US equities |
SPCX $167.58 ▲+5.42% NVDA $236.69 ▲+1.17% MU $1,067.47 ▼-0.69% TSLA $378.96 ▲+2.26% MSFT $526.37 ▲+1.71% SNDK $1,711.51 ▼-0.49% INTC $117.08 ▼-1.89% META $744.34 ▲+2.23%
FinancialContent

Articles published by Altamira Therapeutics Ltd

News headline image
Altamira Therapeutics Announces Collaboration on Circular RNA Delivery
From Altamira Therapeutics Ltd
Via GlobeNewswire
Tickers CYTOF
News headline image
Altamira Therapeutics Provides Business Update, Reports Full Year 2024 Financial Results
From Altamira Therapeutics Ltd
Via GlobeNewswire
Tickers CYTOF
News headline image
Altamira Therapeutics to Host Full Year 2024 Financial Results and Business Update Call on April 30, 2025
From Altamira Therapeutics Ltd
Via GlobeNewswire
Tickers CYTOF
News headline image
Altamira Announces Notice of Allowance from USPTO for Bentrio Nasal Spray Patent
From Altamira Therapeutics Ltd
Via GlobeNewswire
Tickers CYTOF
News headline image
Altamira Therapeutics Announces Collaboration on Radiopharmaceutical Targeting Strategies
From Altamira Therapeutics Ltd
Via GlobeNewswire
Tickers CYTOF
News headline image
Altamira Therapeutics Announces Successful Nanoparticle-Based Delivery of Circular RNA
From Altamira Therapeutics Ltd
Via GlobeNewswire
Tickers CYTOF
News headline image
Altamira Therapeutics Announces Transition from NASDAQ to OTC Markets
From Altamira Therapeutics Ltd
Via GlobeNewswire
Tickers CYTO
News headline image
Altamira Therapeutics Provides Update on Nasdaq Listing
From Altamira Therapeutics Ltd
Via GlobeNewswire
Tickers CYTO
News headline image
Altamira Therapeutics Announces Extended ISO 13485 Quality Management System Certification for Bentrio Nasal Spray
From Altamira Therapeutics Ltd
Via GlobeNewswire
Tickers CYTO
News headline image
Altamira Therapeutics Provides Business Update and First Half 2024 Financial Results
From Altamira Therapeutics Ltd
Via GlobeNewswire
Tickers CYTO
News headline image
Altamira Therapeutics to Host First Half 2024 Financial Results and Business Update Call on September 24, 2024
From Altamira Therapeutics Ltd
Via GlobeNewswire
Tickers CYTO
News headline image
Altamira Therapeutics Announces Closing of up to $12.0 Million Public Offering
From Altamira Therapeutics Ltd
Via GlobeNewswire
Tickers CYTO
News headline image
Altamira Therapeutics Announces Pricing of up to $12.0 Million Public Offering
From Altamira Therapeutics Ltd
Via GlobeNewswire
Tickers CYTO
News headline image
Altamira Therapeutics Announces Expansion of Bentrio License and Distribution Agreement with Nuance Pharma in East and South East Asia
From Altamira Therapeutics Ltd
Via GlobeNewswire
Tickers CYTO
News headline image
Altamira Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference September 9-11
From Altamira Therapeutics Ltd
Via GlobeNewswire
Tickers CYTO
News headline image
Altamira Therapeutics Announces Extension of Bentrio Distribution Agreement with Pharma Nordic to Include Sweden and Denmark
From Altamira Therapeutics Ltd
Via GlobeNewswire
Tickers CYTO
News headline image
Altamira Therapeutics Announces Confirmed Suitability of Bentrio for Athletes as Comprehensive Testing Shows Absence of Prohibited Substances
From Altamira Therapeutics Ltd
Via GlobeNewswire
Tickers CYTO
News headline image
Altamira Therapeutics Announces Significant Enhancement of Immune Checkpoint Inhibition Therapy in Combination with Zbtb46 mRNA Delivered with SemaPhore Nanoparticles in Animal Tumor Models
From Altamira Therapeutics Ltd
Via GlobeNewswire
Tickers CYTO
News headline image
Altamira Therapeutics Announces Publication of Preclinical Data Showing Successful Treatment of Abdominal Aortic Aneurysm with SOD2 mRNA Delivered by SemaPhore Nanoparticles
From Altamira Therapeutics Ltd
Via GlobeNewswire
Tickers CYTO
News headline image
Altamira Therapeutics Highlights Newly Published Review Article Supporting Use of Betahistine in Vertigo Management
From Altamira Therapeutics Ltd
Via GlobeNewswire
Tickers CYTO
News headline image
Altamira Therapeutics Provides Business Update
From Altamira Therapeutics Ltd
Via GlobeNewswire
Tickers CYTO
News headline image
Altamira Therapeutics Announces Dissemination of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis Through Social Media Channels of Top Allergy Journal
From Altamira Therapeutics Ltd
Via GlobeNewswire
Tickers CYTO
News headline image
Altamira Therapeutics Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles with siRNA Targeting p65 Protein in Treatment of Cancer and Inflammation
From Altamira Therapeutics Ltd
Via GlobeNewswire
Tickers CYTO
News headline image
Altamira Therapeutics Announces Publication of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis in Top Peer Reviewed Journal
From Altamira Therapeutics Ltd
Via GlobeNewswire
Tickers CYTO
News headline image
Altamira Therapeutics Provides Business Update, Reports Full Year 2023 Financial Results
From Altamira Therapeutics Ltd
Via GlobeNewswire
Tickers CYTO
News headline image
Altamira Therapeutics to Host Full Year 2023 Financial Results and Business Update Call on April 10, 2024
From Altamira Therapeutics Ltd
Via GlobeNewswire
Tickers CYTO
News headline image
Altamira Therapeutics Announces Collaboration with Univercells Group on Nanoparticle-Delivered mRNA Vaccines
From Altamira Therapeutics Ltd
Via GlobeNewswire
Tickers CYTO
News headline image
Altamira Therapeutics’ Peptide-Based Delivery Platform Shown to Enhance Potency of Commonly Used Gene Delivery Method as Published in Peer-Reviewed Journal
From Altamira Therapeutics Ltd
Via GlobeNewswire
Tickers CYTO
News headline image
Altamira Therapeutics Files Second Provisional Patent Application for OligoPhore Nanoparticles Targeting Different KRAS Mutations in Cancer Treatment
From Altamira Therapeutics Ltd
Via GlobeNewswire
Tickers CYTO
News headline image
Altamira Therapeutics to Present at 3rd Annual mRNA-Based Therapeutics Summit
From Altamira Therapeutics Ltd
Via GlobeNewswire
Tickers CYTO